Condylar osteomyelitis: A case report of a rare complication of maxillary dental extraction.

Condylar osteomyelitis is a long-standing infection of the condylar head of the mandible. The chronic progression of this disease can lead to the destruction of surrounding bony structures and can ultimately affect function. Currently, in English Literature, there have been few cases published on condylar osteomyelitis. Interestingly, regardless of proximity, there have only been two other reported cases of condylar osteomyelitis subsequent to extractions of the upper maxillary third molar. We report a case of a 27-year-old female who presented with an acute episode of condylar osteomyelitis after a simple extraction of an upper left third molar. Several courses of antibiotics did not alleviate her severe trismus, paresthesia, or extensive preauricular collection. Three surgical interventions showed negative growth on numerous swabs. However, CT scans and an MRI confirmed extensive osteomyelitis along the left head, neck, and the angle of the mandible. Following inpatient IV antibiotics, the patient was discharged with a PICC line to allow for long-term treatment. An improvement in function, pain, and swelling was seen on discharge. However, due to the nature of this disease she was monitored for 2 years and due to joint collapse has been listed for alloplastic replacement.

Pembrolizumab-induced Myasthenia Gravis: Literature Review of Ocular Manifestations and a Refractory Case.

Immune checkpoint inhibition is a new and promising therapy approved for the treatment of various malignancies. Pembrolizumab is a potent tumor suppressor that acts by upregulating the immune system to recognize cancer cells which may result in disrupted self-tolerance. We describe a case and perform a literature review of myasthenia gravis with ocular manifestations after treatment with pembrolizumab. Our case had bilateral ptosis refractory to conventional treatment, and she remained functionally blind as a result. The literature review included 28 cases of immune-related myasthenia gravis, and a 30% mortality rate excluding deaths from primary cancer progression was shown. Under half had full symptom resolution (n=13, 46%), and there was no clear correlation between specific management strategies and prognosis. Patients with isolated ocular myasthenia gravis (n=9, 32%) were twice as likely to be symptom-free after treatment compared with generalized myasthenia gravis (75% vs. 39%). Respiratory involvement was associated with twice the mortality rate (60% vs. 33%) and triple the risk of noncomplete symptom resolution (20% vs. 61%). The majority of cases had their pembrolizumab discontinued (n=20, 71%), but 3 were successfully rechallenged by utilizing prophylactic low-dose steroids. Patients with immune-related myasthenia gravis experience increased mortality and morbidity but if steroid-responsive, may benefit from the reintroduction of anti-programmed cell death protein 1 therapy for end-stage malignancy with close monitoring. A high index of clinical suspicion for immune-related adverse effects are critical in an era of rising immunotherapy use.